13 July 2017 - Pope Woodhead, UK

Over the last few years there has been a significant investment in to a pipeline of cell and gene therapy products across oncology as well as in rare diseases and diseases with high unmet needs. While the pipeline of products offer the promise of transforming treatment and outcomes for patients, there are certain environmental and product related barriers to access and/or utilisation.

Read more ...

11 May 2017 - Pope Woodhead, UK

As digital market access negotiation gets sophisticated, it is pushing the evolution of global and local Market Access roles. Whether ready or not, Digital has landed in Pharma, and if other industries are anything to go by, it’s here to stay and the rate of progress will be rapid.

In terms of customer engagement, particularly local access negotiations, digital provides significant new opportunities to connect global to national and local activities for companies willing to reassess their outputs and how they work organisationally.  However, as with any change, fear of failure may be causing paralysis.

Read more ...

04 May 2017 - Pope Woodhead, UK

The pharmaceutical industry should improve how they interact with HCPs and Patients, and digital technology can play a significant role in this process. The use of digital does however introduce a number of issues and challenges that need to be tackled including; accessibility, connectivity, technology, legal (e.g. data protection) and medicines regulations.

Read more ...

27 April 2017 - Pope Woodhead, UK

Digital technologies have the potential to transform the pharmaceutical industry, driving patient centric solutions, more efficient business models and new commercial opportunities. And yet the adoption of digital by the pharma lags way behind other global industries. Pharma companies need to evolve a coherent digital strategy sooner rather than later or get left behind.

Read more ...

28 February 2017 - Pope Woodhead, UK

While globalisation creates huge opportunities for the pharmaceutical industry, it also raises a number of challenges. Pharmaceutical companies increasingly need to share information and insights rapidly and efficiently with parties across the globe so that they can react appropriately to both global and local needs. Fostering a collaborative mindset is one approach that can help to address these needs.

Read more ...

2 February 2017 - Pope Woodhead, UK

Market access of orphan drugs (ODs) in Asia is challenged by high cost, limited data and lack of awareness in some cases. Such challenges intensify in recent years with increasing budget constraint.Payers and policy makers in

Asia (e.g. Australia and Japan) have already started to explore new ways to manage healthcare expenditure, some of which will impact market access of ODs in these areas.

 

Read more ...

16 February 2017 - Pope Woodhead, UK

Mark Perrott, Pope Woodhead and Katherine Long, AgilePV discussed in this webinar how can you effectively track your RMPs across various products, markets and safety concerns and efficiently ensure compliance by centralisng and tracking your RMP activities with dedicated software which is accessible to local affiliates and provides global transparency and governance.

Read more ...

7 December 2016 - Pope Woodhead, UK

Pharmaceutical companies are increasingly expected to take a more structured approach for benefit-risk assessment. This has been driven by a variety of initiatives over the past several years. The recently adopted ICH M4E(R2) guideline also provides a new format for benefit-risk conclusions within CTD regulatory submissions.

How can a company effectively perform benefit-risk assessments during a product’s life cycle? In this webinar Dr Steve Mayall, a Principal Consultant in Pope Woodhead’s Development Consulting practice presented how these evaluations are critical, impacting many downstream activities and deliverables. Relevant stakeholders may encompass regulators, payers, healthcare professionals and patients.

Read more ...

1 December 2016 - Pope Woodhead, UK

Contracting, alternative access pathways and evidence development

Limited healthcare budgets, politics and innovative new therapies are increasing pressure on pharmaceutical pricing. For many high cost therapies coming to market, it is now a prerequisite to establish alternative access strategies in some geographies. This can take the form of alternative access pathways, novel pricing/contracting approaches or evidence development initiatives. These strategies are also being used to gain a commercial edge and insulate marketed products from fierce competition. Establishing the appropriate deployment of each access strategy and measuring the benefits is imperative to drive commercial success.

Read more ...

24 November 2016 - Pope Woodhead, UK

The investment required, risks involved in developing new specialised and sophisticated medicines, coupled with increase in stakeholder expectations the challenges have never been greater. Additionally, markets for products are more competitive and return on investment uncertain at early stages of product development.

Richard Huckle, a Senior Consultant in Pope Woodhead’s Development Consulting practice, presented on regulatory tools that help navigate the ever increasing list of stakeholder requirements/expectations and how these regulatory ‘tools’ enable more efficient clinical development and ultimately, patients’ earlier access to promising medicines.

 

Read more ...

Contact Us

Please fill out the form below to request more information on an Event/Webinar. Alternatively email 




Webinars Archive